Filing Details
- Accession Number:
- 0001140361-10-028673
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-07-07 13:00:00
- Reporting Period:
- 2010-07-06
- Filing Date:
- 2010-07-07
- Accepted Time:
- 2010-07-07 14:36:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1184149 | W Jonathan Ayers | One Idexx Drive Westbrook ME 04092 | Chairman, President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-07-06 | 50,000 | $12.60 | 246,081 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-07-06 | 25,800 | $60.36 | 220,281 | No | 4 | S | Direct | |
Common Stock | Disposition | 2010-07-06 | 14,925 | $61.48 | 205,356 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2010-07-06 | 50,000 | $0.00 | 50,000 | $12.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
540,320 | 2012-01-28 | No | 4 | M | Direct |
Footnotes
- Includes 107 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 6/30/2010.
- The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/3/2009.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $60.01 to $61.00, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $61.02 to $62.00, inclusive.
- Grant of options to buy shares of common stock which vest in five equal annual installments, beginning on the first anniversary date (1/28/2003) of the date of grant.